Free Trial

Veracyte (VCYT) Stock Price, News & Analysis

+0.65 (+3.13%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
643,122 shs
Average Volume
656,349 shs
Market Capitalization
$1.64 billion
P/E Ratio
Dividend Yield
Price Target

Veracyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
28.2% Upside
$27.50 Price Target
Short Interest
5.86% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.93mentions of Veracyte in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$216,500 Sold Last Quarter
Proj. Earnings Growth
From ($0.19) to $0.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.69 out of 5 stars

Medical Sector

240th out of 931 stocks

Medical Laboratories Industry

8th out of 19 stocks

VCYT stock logo

About Veracyte Stock (NASDAQ:VCYT)

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Stock Price History

VCYT Stock News Headlines

Veracyte (VCYT) Fell Due to a Lack of Rising Profitability
Here's what to expect from Veracyte's earnings
Veracyte, Inc. (VCYT)
What Makes Veracyte (VCYT) a Lucrative Investment?
VCYT Apr 2024 30.000 call
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$361.05 million
Cash Flow
$0.10 per share
Book Value
$14.30 per share


Free Float
Market Cap
$1.64 billion

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Marc A. StapleyMr. Marc A. Stapley (Age 54)
    CEO & Director
    Comp: $1.55M
  • Ms. Rebecca  ChambersMs. Rebecca Chambers (Age 46)
    Executive VP & CFO
    Comp: $901.49k
  • Dr. Phillip G. Febbo M.D. (Age 58)
    Chief Scientific & Medical Officer
    Comp: $657.74k
  • Ms. Annie McGuire (Age 43)
    Executive VP, General Counsel & Chief People Officer
    Comp: $791.72k
  • Dr. John Leite Ph.D. (Age 52)
    Chief Commercial Officer for CLIA Business
    Comp: $1.53M
  • Mr. Jonathan Wygant (Age 53)
    VP & Chief Accounting Officer
  • Mr. Steven French
    Senior VP & Chief Information Officer
  • Ms. Karen Possemato
    Senior Vice President of Corporate Marketing, Communications & Commercial Operations
  • Mr. Robert Brainin (Age 53)
    Executive VP & Chief Business Officer
  • Ms. Corinne Danan
    Senior Vice President

VCYT Stock Analysis - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price target for 2024?

5 Wall Street research analysts have issued 1 year target prices for Veracyte's shares. Their VCYT share price targets range from $21.00 to $34.00. On average, they expect the company's stock price to reach $27.50 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2024?

Veracyte's stock was trading at $27.51 at the start of the year. Since then, VCYT shares have decreased by 22.0% and is now trading at $21.45.
View the best growth stocks for 2024 here

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our VCYT earnings forecast

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) posted its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.17. The biotechnology company had revenue of $96.84 million for the quarter, compared to the consensus estimate of $93.35 million. Veracyte had a negative net margin of 18.16% and a negative trailing twelve-month return on equity of 1.42%. Veracyte's revenue was up 17.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.11) EPS.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $402.0 million-$410.0 million, compared to the consensus revenue estimate of $397.8 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Who are Veracyte's major shareholders?

Veracyte's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.66%), Sumitomo Mitsui Trust Holdings Inc. (4.46%), Nikko Asset Management Americas Inc. (4.38%), Champlain Investment Partners LLC (3.53%), Bamco Inc. NY (1.46%) and William Blair Investment Management LLC (0.97%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji.
View institutional ownership trends

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Veracyte have any subsidiaries?
The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
This page (NASDAQ:VCYT) was last updated on 5/29/2024 by Staff

From Our Partners